Furthermore, the continual dependency of KRAS mutant NSCLC on upstream receptor tyrosine kinases including HER3, as well as the dynamic kinome reprograming after MAPK pathway inhibition117, provides a strong scientific rationale for combining these drug classes with HER3-DXd. Here, KRAS is linked to non-small cell lung carcinoma.